Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis
| العنوان: | Dendrimers toward Translational Nanotherapeutics: Concise Key Step Analysis |
|---|---|
| المؤلفون: | Ángeles Muñoz-Fernández, João Rodrigues, Jean-Pierre Majoral, René Roy, Serge Mignani, Xiangyang Shi, Valentín Ceña |
| المساهمون: | Laboratoire de Chimie et de Biochimie Pharmacologiques et Toxicologiques (LCBPT - UMR 8601), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Paris (UP), Centro de Química da Madeira, Universidade da Madeira (UMA), Glycovax Pharma, State Key Laboratory for Fiber & Material Modification of Donghua University, Donghua University [Shanghai], Northwestern Polytechnical University [Xi'an] (NPU), Hospital General Universitario 'Gregorio Marañón' [Madrid], Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), Spanish HIV-HGM BioBank (SHIVBB), Virtual Institute on Poverty Related Diseases, Biomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Instituto de Salud Carlos III [Madrid] (ISC)-ministerio de ciencia e innovacion, Centro de Investigacion Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Instituto de Salud Carlos III [Madrid] (ISC), Universidad de Castilla-La Mancha (UCLM), Laboratoire de chimie de coordination (LCC), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie de Toulouse (ICT-FR 2599), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), PRC NSFC-CNRS 2019 (21911530230, 199675), FCT-Fundação para a Ciência e a Tecnologia (Base Fund UIDB/00674/2020 and Programmatic Fund UIDP/00674/2020, Portuguese Government Funds), ARDITI-Agência Regional para o Desenvolvimento da Investigação Tecnologia e Inovação through Project M1420-01- 0145-FEDER-000005-CQM+ (Madeira 14-20 Program), Transnational EuroNanoMed III (ERANET), Spanish Ministerio de Economía y Competitividad (Project SAF2017-89288-R from MINECO/AEI/FEDER/UE) and JCCM (Project SBPLY/19/180501/000067), RD16/0025/0019 and PI16/01863 projects as part of the Acción Estratégica en Salud, Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica by ISCIII, Fondos FEDER and CIBER BBN, RIS Cohort (CoRIS) is funded by the ISCIII through the Spanish AIDS Research Network (RIS C03/173 and RD12/0017/0018) Action, COST Action Ca 17140 and NAW European Project, CNRS |
| المصدر: | Bioconjugate Chemistry Bioconjugate Chemistry, American Chemical Society, 2020, 31 (9), pp.2060-2071. ⟨10.1021/acs.bioconjchem.0c00395⟩ |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Dendrimers, Cancer therapy, Biomedical Engineering, Pharmaceutical Science, Contrast Media, Bioengineering, 02 engineering and technology, 01 natural sciences, Drug Delivery Systems, Animals, Humans, Nanotechnology, [CHIM.COOR]Chemical Sciences/Coordination chemistry, Pharmacology, Dendrons, Drug Carriers, 010405 organic chemistry, Chemistry, Pharmaceutics, Organic Chemistry, 021001 nanoscience & nanotechnology, 0104 chemical sciences, 3. Good health, Clinical Practice, Nanomedicine, Pharmaceutical Preparations, Key (cryptography), Pharmaceuticals, Nanoparticles, Engineering ethics, sense organs, 0210 nano-technology, Biotechnology |
| الوصف: | International audience; The goal of nanomedicine is to address specific clinical problems optimally, to fight human diseases, and to find clinical relevance to change clinical practice. Nanomedicine is poised to revolutionize medicine via the development of more precise diagnostic and therapeutic tools. The field of nanomedicine encompasses numerous features and therapeutic disciplines. A plethora of nanomolecular structures have been engineered and developed for therapeutic applications based on their multitasking abilities and the wide functionalization of their core scaffolds and surface groups. Within nanoparticles used for nanomedicine, dendrimers as well polymers have demonstrated strong potential as nanocarriers, therapeutic agents, and imaging contrast agents. In this review, we present and discuss the different criteria and parameters to be addressed to prepare and develop druggable nanoparticles in general and dendrimers in particular. We also describe the major requirements, included in the preclinical and clinical roadmap, for NPs/dendrimers for the preclinical stage to commercialization. Ultimately, we raise the clinical translation of new nanomedicine issues. |
| تدمد: | 1520-4812 1043-1802 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03f0a67f869851d275bf460431aa532d https://pubmed.ncbi.nlm.nih.gov/32786368 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....03f0a67f869851d275bf460431aa532d |
| قاعدة البيانات: | OpenAIRE |
Find this issue from the American Chemical Society | تدمد: | 15204812 10431802 |
|---|